Mylan CEO Heather Bresch appeared on CNBC for nearly 20 minutes on Thursday to explain the drastic price rise of her company's emergency allergy EpiPens, and she had a culprit: "the system."
Bresch, the daughter of Sen. Joe Manchin (D., W.V.), makes $19 million a year as Mylan's CEO, and the EpiPen price has surged from about $100 in 2009 to between $600 and $700 today. Yet, she insisted, the health care and pharmaceutical "system" was the problem:
"We have an outdated, inefficient system."
"The system wasn't build for that."
"So we went around the system."
"The system is broken."
"If you don't play in the system ... in the system that's broken today, your products aren't going to get to patients."
"The system needs fixed [sic]."
"That doesn't excuse an outdated, inefficient system."
"Our system needs to be dynamic to evolve and transform this health care system."
"It's a complicated system.
"The system incentivizes higher prices."
"The system incentivizes higher prices."
"The system incentivizes higher prices on the brand."
You can't trust the system.